EPPIC-Net: Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy
NCT ID: NCT05476276
Last Updated: 2025-12-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
127 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-09-21
Study Completion Date
2025-08-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a Platform Protocol to perform Phase II clinical trials in The Early Phase Pain Investigation Clinical Network (EPPIC-Net), under The Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, related to the treatment of Painful Diabetic Peripheral Neuropathy (PDPN) in a platform setting to test multiple assets under a single protocol.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA
NCT05480228
Painful Diabetic Neuropathy
COMPLETED
PHASE2
Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy
NCT03176472
Painful Diabetic Peripheral Neuropathy
COMPLETED
PHASE2
Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
NCT02673866
Neuropathic Pain
Diabetes
WITHDRAWN
PHASE2
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain
NCT04476108
Diabetic Peripheral Neuropathic Pain
COMPLETED
PHASE2
Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
NCT02372578
Painful Diabetic Peripheral Neuropathy (PDPN)
TERMINATED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a Platform Protocol that allows evaluation of more than one treatment in a single trial structure, to be run within EPPIC-Net. Instead of testing individual assets in a series of clinical trials, this Platform Protocol sets out the framework for testing multiple assets related to PDPN. This provides an efficient approach to evaluate multiple therapies under a single infrastructure in a timely fashion. The Platform Protocol also allows efficiencies by creating the possibility of sharing information across assets, such as data from control conditions.
This Platform Protocol is for a platform design to allow for the testing of multiple assets. Some platform trials allow direct comparisons of competing therapies for the same condition. However, for this EPPIC-Net platform trial, there will not be direct comparisons of assets to one another. Instead, assets will only be compared to a placebo. This is in service to the EPPIC-Net primary goal of accelerating the development of pain treatment because, based on feedback from asset-holders, the possibility of comparison of assets to one another or to an active drug would be a deterrent for asset-holders' participation in EPPIC-Net.
This Platform Protocol is for a platform design to allow for the testing of multiple assets. Some platform trials allow direct comparisons of competing therapies for the same condition. However, for this EPPIC-Net platform trial, there will not be direct comparisons of assets to one another. Instead, assets will only be compared to a placebo. This is in service to the EPPIC-Net primary goal of accelerating the development of pain treatment because, based on feedback from asset-holders, the possibility of comparison of assets to one another or to an active drug would be a deterrent for asset-holders' participation in EPPIC-Net.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Painful Diabetic Neuropathy
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
The Platform Protocol is intended to potentially accommodate different design plans for different assets. In addition, it is anticipated that the protocol may evolve over time, as lessons learned from earlier assets are used to fine tune the study design for later assets in an adaptive approach. For reasons of generalizability (including consideration of minimizing participant burden and being attractive to asset holders), a parallel-group design will typically be employed, and it is the current intention that designs should provide 80% power to detect an effect size of 0.35 on the primary efficacy outcome
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Randomization assignment within an ISA will be blinded from study participants, staff from clinical sites, investigators, asset owners, IND sponsors, and/or designees. This blinding will be accomplished by providing identical investigational product and packaging for each asset and its corresponding control treatment. The use of IXRS will ensure the blinding is accomplished.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EN21-01 ISA
The EN21-01 Intervention Specific Analysis is detailed in the protocol (NCT#)
Group Type
EXPERIMENTAL
ISA specific
Intervention Type
DRUG
ISA specific interventions will be listed in their protocols.
Placebo Comparator
Each ISA will detail the use of the Placebo Comparator.
Group Type
PLACEBO_COMPARATOR
ISA specific
Intervention Type
DRUG
ISA specific interventions will be listed in their protocols.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ISA specific
ISA specific interventions will be listed in their protocols.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Able to provide informed consent. Legally Authorized Representatives (LARs) are not allowed, but impartial witnesses may be utilized as needed for visually impaired participants.
2. 18 years of age and older
3. Diagnosis of diabetes mellitus
4. Meets the Toronto Criteria for probable clinical sensorimotor polyneuropathy, with PDPN symptoms present for at least six months. This is defined as a combination of symptoms and signs with any two or more of the following (must be present bilaterally in the distal lower extremities): neuropathic symptoms, decreased distal sensation, or unequivocally decreased (or absent) ankle reflexes. Specifically:
1. The presence of any neuropathic symptoms on either the "Douleur Neuropathique en 4 Questions" (DN4) or the EPPIC-Net Neuropathy Exam will suffice to demonstrate "neuropathic symptoms."
2. Decreased distal sensation is satisfied by any of the following:
i. "Yes" is checked at least once under Question 3 of the DN4 which queries hypoesthesia to touch and pinprick.
ii. At least one score of "reduced" or "absent" on the right AND at least one score of "reduced" or "absent" on the left in any of the following items from the EPPIC-Net Neuropathy Exam:
* Pin sensation in segments 1 or 2 (i.e. the toes and feet)
* Vibration at the great toe
* Joint position at the great toe
* Light touch/touch pressure at the great toe
* Temperature at the great toe
* Monofilament at the great toe c. Decreased or absent ankle reflexes is satisfied by a score of "reduced" or "absent" on the right AND left in the "Ankle reflex" item in the EPPIC-Net Neuropathy Exam.
5. A score of at least 4 on the "Douleur Neuropathique en 4 Questions" (DN4).
6. Pain reporting during a pre-defined 7-day screening period meets study criteria (to be established using a centrally-administered screening algorithm) which may account for mean pain intensity reported, variability in reported values, and adherence in reporting.
7. Patient reported daily 11-point NRS (for average and worst pain over the last 24 hours) is completed on at least 5 out of the 7 days in the screening and baseline periods.
8. Participants must be willing and able to comply with scheduled visits, the treatment schedule, laboratory testing, and other requirements of the study (e.g., completion of app-based daily reporting).
9. Females may be included if they meet at least one of the following criteria (note that individual ISAs may specify more stringent measures to prevent pregnancy):
a. Are not of childbearing potential, defined as one or more of the following: i. Post-menopausal for at least 1 year ii. Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) iii. XY genotype iv. Turner syndrome v. Uterine agenesis. b. Are completely abstinent from sexual activity capable of resulting in pregnancy (as part of their preferred and usual lifestyle). This will include females whose sole sexual partner is a male who has undergone surgical sterilization or vasectomy.
c. Women of childbearing potential will agree to practice an effective form of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly. This must be done before, throughout, and for 30 days after the last dose of DB study drug. Acceptable methods are: i. Hormonal methods such as the vaginal ring, or oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the participant's usual menstrual cycle period) before study drug administration.
ii. Intrauterine device. iii. Barrier method of contraception: condoms with or without a spermicidal agent, diaphragm or cervical cap with spermicide
10. Specific requirements of male participants (regarding contraception) will be defined in the ISAs based on the potential toxicity profile of the asset.
2. 18 years of age and older
3. Diagnosis of diabetes mellitus
4. Meets the Toronto Criteria for probable clinical sensorimotor polyneuropathy, with PDPN symptoms present for at least six months. This is defined as a combination of symptoms and signs with any two or more of the following (must be present bilaterally in the distal lower extremities): neuropathic symptoms, decreased distal sensation, or unequivocally decreased (or absent) ankle reflexes. Specifically:
1. The presence of any neuropathic symptoms on either the "Douleur Neuropathique en 4 Questions" (DN4) or the EPPIC-Net Neuropathy Exam will suffice to demonstrate "neuropathic symptoms."
2. Decreased distal sensation is satisfied by any of the following:
i. "Yes" is checked at least once under Question 3 of the DN4 which queries hypoesthesia to touch and pinprick.
ii. At least one score of "reduced" or "absent" on the right AND at least one score of "reduced" or "absent" on the left in any of the following items from the EPPIC-Net Neuropathy Exam:
* Pin sensation in segments 1 or 2 (i.e. the toes and feet)
* Vibration at the great toe
* Joint position at the great toe
* Light touch/touch pressure at the great toe
* Temperature at the great toe
* Monofilament at the great toe c. Decreased or absent ankle reflexes is satisfied by a score of "reduced" or "absent" on the right AND left in the "Ankle reflex" item in the EPPIC-Net Neuropathy Exam.
5. A score of at least 4 on the "Douleur Neuropathique en 4 Questions" (DN4).
6. Pain reporting during a pre-defined 7-day screening period meets study criteria (to be established using a centrally-administered screening algorithm) which may account for mean pain intensity reported, variability in reported values, and adherence in reporting.
7. Patient reported daily 11-point NRS (for average and worst pain over the last 24 hours) is completed on at least 5 out of the 7 days in the screening and baseline periods.
8. Participants must be willing and able to comply with scheduled visits, the treatment schedule, laboratory testing, and other requirements of the study (e.g., completion of app-based daily reporting).
9. Females may be included if they meet at least one of the following criteria (note that individual ISAs may specify more stringent measures to prevent pregnancy):
a. Are not of childbearing potential, defined as one or more of the following: i. Post-menopausal for at least 1 year ii. Surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) iii. XY genotype iv. Turner syndrome v. Uterine agenesis. b. Are completely abstinent from sexual activity capable of resulting in pregnancy (as part of their preferred and usual lifestyle). This will include females whose sole sexual partner is a male who has undergone surgical sterilization or vasectomy.
c. Women of childbearing potential will agree to practice an effective form of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly. This must be done before, throughout, and for 30 days after the last dose of DB study drug. Acceptable methods are: i. Hormonal methods such as the vaginal ring, or oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the participant's usual menstrual cycle period) before study drug administration.
ii. Intrauterine device. iii. Barrier method of contraception: condoms with or without a spermicidal agent, diaphragm or cervical cap with spermicide
10. Specific requirements of male participants (regarding contraception) will be defined in the ISAs based on the potential toxicity profile of the asset.
Exclusion Criteria
1. Peripheral neuropathy that is known to have been caused by a condition other than diabetes (e.g. HIV, cancer/chemotherapy-induced, other medication-induced, alcohol-induced, hereditary, autoimmune neuropathies, uncontrolled or untreated hypothyroidism). Note that participants will not be tested for HIV, this will be established by patient report or review of the medical record.
2. Other significant pain conditions involving the same area as the neuropathy (e.g. physical deformity of the feet, plantar fasciitis, lumbosacral radiculopathy with distal lower extremity pain, fibromyalgia involving the lower limbs, Morton's neuroma), that in the opinion of the investigator would interfere with the participant's ability to rate the neuropathy pain.
3. Other pain conditions not involving the same area as the neuropathy which (in the opinion of the investigator) interfere with the participant's ability to rate the neuropathy pain.
4. Any amputation of the lower limb which interferes with the participant's ability to rate the neuropathy pain. If there is any amputation please contact the MM to confirm eligibility prior to randomization to an ISA.
5. The presence of any current foot ulcer.
6. Significant peripheral vascular disease defined as symptoms consistent with intermittent claudication.
7. Use of other investigational drugs within 3 months before screening and throughout the study.
8. Known or suspected hypersensitivity to all of the assets (active component and excipients) currently being tested in the Platform Protocol.
9. Undergone neurolytic or neurosurgical therapy or used an implanted neurostimulating device for neuropathic pain in the distal lower limbs within 3 months of screening.
10. Use of the high dose capsaicin patch (8%) in the 6 months before screening and throughout the study (for the treatment of PDPN). Use of the capsaicin patch in a manner that is not expected to interfere with the measurement of PDPN severity is allowed.
11. Participants who meet any of the following regarding concomitant treatments:
1. Unwilling or unable to discontinue episodic or periodic treatments for pain in the distal legs and/or feet (e.g., injections of local anesthetics).
2. Starting a new non-pharmacological pain treatment (e.g. relaxation/hypnosis, physical or occupational therapy, any exercise-based therapy, any talk-based therapy, acupuncture, TENS) for the treatment of PDPN within 4 weeks prior to screening OR planning on starting a new non-pharmacologic treatment for PDPN OR planned changes to a stable non-pharmacologic treatment for PDPN during the study.
i. Non-pharmacological treatment for conditions other than PDPN is allowed without restriction.
12. Active use of opioids or marijuana for any reason at screening and unwilling or unable to discontinue use.
13. Clinically significant ECG or laboratory abnormalities at the Screening Visit that would put the participant at undue risk or affect the ability of the participant to participate in the trial (in the opinion of the investigator). Screening ECG and lab results may be repeated without requiring a rescreen, as long as the participant is still within the screening window.
14. Participants whose glycemic control has been unstable within 3 months before screening (e.g. ketoacidosis requiring hospitalization).
15. Proliferative retinopathy or maculopathy requiring acute treatment.
16. Requiring dialysis.
17. Myocardial infarction or stroke in the past 6 months.
18. Known diagnosis of moderate to severe hepatic impairment (equivalent to Child-Pugh class B or C) OR aspartate aminotransferase or alanine aminotransferase ≥ 3 times the upper limit of normal during the screening process.
19. A clinically significant illness or operative procedure within 4 weeks of screening.
20. Clinically significant surgery planned during the study period. If a surgery is planned, please contact the MM for approval before randomization.
21. History of malignancy or other medical condition that would put the participant at undue risk or affect the ability of the participant to participate in the trial (in the opinion of the investigator).
23. A clinically significant psychiatric disease that would put the participant at undue risk or affect the ability of the participant to participate in the trial (in the opinion of the investigator).
24. Alcohol use disorder or other substance use disorders (other than nicotine or caffeine) in accordance with DSM-5 criteria within 12 months of screening.
25. Positive urine drug tests defined as one or more of the following (see Urine Drug Testing Section 6.2.13.5.1):
1. Two positive urine drug tests for a prescribed opioid (buprenorphine, opiates, methadone and/or oxycodone), prior to the initiation of investigational product (IP);
2. Two positive urine drug tests for marijuana (prescribed or recreational), prior to the initiation of investigational product (IP);
3. One positive urine drug test for cocaine, ecstasy, methamphetamines, or phencyclidine (PCP);
4. One positive urine drug test for non-prescribed amphetamines, barbiturates, benzodiazepines, or opioids (buprenorphine, opiates, methadone and/or oxycodone).
26. Vulnerable persons defined as either of the following:
1. Individuals whose willingness to volunteer in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.
Individuals whose judgment has been impaired by their physical, mental, or socio-economical condition and those incapable of giving informed consent.
2. Other significant pain conditions involving the same area as the neuropathy (e.g. physical deformity of the feet, plantar fasciitis, lumbosacral radiculopathy with distal lower extremity pain, fibromyalgia involving the lower limbs, Morton's neuroma), that in the opinion of the investigator would interfere with the participant's ability to rate the neuropathy pain.
3. Other pain conditions not involving the same area as the neuropathy which (in the opinion of the investigator) interfere with the participant's ability to rate the neuropathy pain.
4. Any amputation of the lower limb which interferes with the participant's ability to rate the neuropathy pain. If there is any amputation please contact the MM to confirm eligibility prior to randomization to an ISA.
5. The presence of any current foot ulcer.
6. Significant peripheral vascular disease defined as symptoms consistent with intermittent claudication.
7. Use of other investigational drugs within 3 months before screening and throughout the study.
8. Known or suspected hypersensitivity to all of the assets (active component and excipients) currently being tested in the Platform Protocol.
9. Undergone neurolytic or neurosurgical therapy or used an implanted neurostimulating device for neuropathic pain in the distal lower limbs within 3 months of screening.
10. Use of the high dose capsaicin patch (8%) in the 6 months before screening and throughout the study (for the treatment of PDPN). Use of the capsaicin patch in a manner that is not expected to interfere with the measurement of PDPN severity is allowed.
11. Participants who meet any of the following regarding concomitant treatments:
1. Unwilling or unable to discontinue episodic or periodic treatments for pain in the distal legs and/or feet (e.g., injections of local anesthetics).
2. Starting a new non-pharmacological pain treatment (e.g. relaxation/hypnosis, physical or occupational therapy, any exercise-based therapy, any talk-based therapy, acupuncture, TENS) for the treatment of PDPN within 4 weeks prior to screening OR planning on starting a new non-pharmacologic treatment for PDPN OR planned changes to a stable non-pharmacologic treatment for PDPN during the study.
i. Non-pharmacological treatment for conditions other than PDPN is allowed without restriction.
12. Active use of opioids or marijuana for any reason at screening and unwilling or unable to discontinue use.
13. Clinically significant ECG or laboratory abnormalities at the Screening Visit that would put the participant at undue risk or affect the ability of the participant to participate in the trial (in the opinion of the investigator). Screening ECG and lab results may be repeated without requiring a rescreen, as long as the participant is still within the screening window.
14. Participants whose glycemic control has been unstable within 3 months before screening (e.g. ketoacidosis requiring hospitalization).
15. Proliferative retinopathy or maculopathy requiring acute treatment.
16. Requiring dialysis.
17. Myocardial infarction or stroke in the past 6 months.
18. Known diagnosis of moderate to severe hepatic impairment (equivalent to Child-Pugh class B or C) OR aspartate aminotransferase or alanine aminotransferase ≥ 3 times the upper limit of normal during the screening process.
19. A clinically significant illness or operative procedure within 4 weeks of screening.
20. Clinically significant surgery planned during the study period. If a surgery is planned, please contact the MM for approval before randomization.
21. History of malignancy or other medical condition that would put the participant at undue risk or affect the ability of the participant to participate in the trial (in the opinion of the investigator).
23. A clinically significant psychiatric disease that would put the participant at undue risk or affect the ability of the participant to participate in the trial (in the opinion of the investigator).
24. Alcohol use disorder or other substance use disorders (other than nicotine or caffeine) in accordance with DSM-5 criteria within 12 months of screening.
25. Positive urine drug tests defined as one or more of the following (see Urine Drug Testing Section 6.2.13.5.1):
1. Two positive urine drug tests for a prescribed opioid (buprenorphine, opiates, methadone and/or oxycodone), prior to the initiation of investigational product (IP);
2. Two positive urine drug tests for marijuana (prescribed or recreational), prior to the initiation of investigational product (IP);
3. One positive urine drug test for cocaine, ecstasy, methamphetamines, or phencyclidine (PCP);
4. One positive urine drug test for non-prescribed amphetamines, barbiturates, benzodiazepines, or opioids (buprenorphine, opiates, methadone and/or oxycodone).
26. Vulnerable persons defined as either of the following:
1. Individuals whose willingness to volunteer in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.
Individuals whose judgment has been impaired by their physical, mental, or socio-economical condition and those incapable of giving informed consent.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New York University
OTHER
Sponsor Role
collaborator
Icahn School of Medicine at Mount Sinai
OTHER
Sponsor Role
collaborator
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Sponsor Role
collaborator
James P. Rathmell, MD
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
James P. Rathmell, MD
Chair, Department of Anesthesiology, Perioperative and Pain Medicine
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jessica Robinson-Papp, MD
Role: PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, San Diego
San Diego, California, United States
Site Status
South Lake Pain Institute
Clermont, Florida, United States
Site Status
SIMEDHealth LLC
Gainesville, Florida, United States
Site Status
University of Florida
Gainesville, Florida, United States
Site Status
Northwestern Department of Neurology
Chicago, Illinois, United States
Site Status
Healthcare Research Network (Flossmoor)
Flossmoor, Illinois, United States
Site Status
University of Kansas Medical Center
Kansas City, Kansas, United States
Site Status
University of Maryland - Baltimore
Baltimore, Maryland, United States
Site Status
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Site Status
MGH Department of Anesthesia, Critical Care, and Pain
Boston, Massachusetts, United States
Site Status
Healthcare Research Network (Hazelwood)
Hazelwood, Missouri, United States
Site Status
Columbia University Medical Center/Neurological Institute
New York, New York, United States
Site Status
Mount Sinai School of Medicine
New York, New York, United States
Site Status
University of Rochester
Rochester, New York, United States
Site Status
Clinical Inquest Center
Beavercreek, Ohio, United States
Site Status
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Site Status
Low Country Pain Center
Orangeburg, South Carolina, United States
Site Status
Nerve and Muscle Center of Texas
Houston, Texas, United States
Site Status
University of Utah School of Medicine
Salt Lake City, Utah, United States
Site Status
Eastern Virginia Medical School
Norfolk, Virginia, United States
Site Status
VCU Department of Neurology
Richmond, Virginia, United States
Site Status
University of Washington
Seattle, Washington, United States
Site Status
University of Wisconsin
Madison, Wisconsin, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022P002381 (EN21-PP)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)
NCT01564459
COMPLETED
PHASE2
A Study for Treatment of Pain in Patients With Diabetic Neuropathy.
NCT00785577
COMPLETED
PHASE2
A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety
NCT02065349
COMPLETED
PHASE2
Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)
NCT00592904
COMPLETED
PHASE2/PHASE3
A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
NCT02215252
COMPLETED
PHASE2
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy
NCT01521598
COMPLETED
PHASE2
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain
NCT04707157
TERMINATED
PHASE2
A Study for the Treatment of Diabetic Peripheral Neuropathic Pain
NCT00552175
COMPLETED
PHASE3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630
RECRUITING
PHASE3
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
NCT06203002
COMPLETED
PHASE2
A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)
NCT00837941
WITHDRAWN
PHASE2
Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT01496365
COMPLETED
PHASE2
Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT00603265
COMPLETED
PHASE2
A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain
NCT05838755
TERMINATED
PHASE2
An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain
NCT00385671
COMPLETED
PHASE4
Dose-effect of SSR180575 in Diabetic Neuropathy
NCT00502515
COMPLETED
PHASE2
Clinical Trial Designed to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy
NCT02435199
WITHDRAWN
PHASE2
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
NCT05620576
COMPLETED
PHASE2
Perineural Injections of Incobotulinumtoxin-A for Diabetic Neuropathic Pain of the Lower Extremities
NCT05623111
RECRUITING
PHASE2
Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy
NCT03172598
COMPLETED
PHASE2
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
NCT04455633
COMPLETED
PHASE2
Study Evaluating EAA-090 in Adult Outpatients With Neuropathic Pain Associated With Diabetic Neuropathy
NCT00073034
TERMINATED
PHASE2
A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)
NCT01556152
WITHDRAWN
PHASE2
Maintenance of Effect of Duloxetine in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
NCT00322621
COMPLETED
PHASE4